Metformin

Metformin, a widely prescribed medication for type 2 diabetes, is being investigated for its potential longevity-promoting effects. Research suggests that metformin may influence several key aging processes. Studies in both humans and animals indicate a potential for decreased mortality and a reduction in certain hallmarks and signs of aging. Specifically, animal studies, including those in monkeys and non-human primates, have shown decreases in hallmarks of aging and general signs of aging. Human studies have demonstrated a reduction in HbA1c levels, a marker of blood sugar control, and some evidence suggests a decrease in mortality.

Beyond its effects on blood sugar, metformin's potential benefits may stem from its influence on cellular processes. Research indicates that metformin can impact autophagy priming, a cellular process involved in removing damaged components. Some studies have also explored its effects on cognitive function and physical capacity. However, findings regarding physical capacity are mixed, with some animal studies showing a decrease.

While the evidence for metformin's longevity benefits is promising, it's important to consider the limitations. The current body of research lacks robust, high-quality evidence such as randomized controlled trials (RCTs) and meta-analyses. Much of the evidence comes from animal studies, and while these provide valuable insights, their findings may not always translate directly to humans. Further rigorous human studies are needed to fully understand metformin's potential role in promoting healthy aging and longevity.